毛细胞白血病2024:诊断、风险分层与治疗更新——血液系统恶性肿瘤年度更新
本文综述毛细胞白血病(HCL)及HCL样疾病的诊断、风险分层与治疗进展。诊断基于毛细胞形态学、HCL免疫学评分3或4分、骨髓活检及BRAFV600E突变。仅症状性患者需治疗,一线用嘌呤类似物(PNA)风险适应化疗,复发/难治用BRAF抑制剂联合利妥昔单抗等,最佳顺序待定。
要点
- 诊断需毛细胞形态学、HCL免疫学评分3或4分、骨髓活检及BRAFV600E突变。
- 仅症状性HCL患者需治疗,一线为风险适应嘌呤类似物化疗。
- 复发/难治可用BRAF抑制剂联合利妥昔单抗、MEK抑制剂、CD22免疫偶联物、BTK抑制剂或Bcl-2抑制剂。
核心结论
- HCL及HCL样疾病是异质性成熟B细胞肿瘤,诊断依赖毛细胞形态、免疫学评分、骨髓活检和BRAFV600E突变。
- 仅症状性患者需治疗,一线为风险适应嘌呤类似物化疗,克拉屈滨联合利妥昔单抗的化学免疫治疗应用渐增。
- 复发/难治基于BRAF抑制剂联合利妥昔单抗、MEK抑制剂、靶向CD22重组免疫偶联物、BTK抑制剂和Bcl-2抑制剂,但最佳治疗顺序尚待确定。
研究设计与样本
- 本文为HCL 2024年度更新综述,汇总HCL及HCL样疾病(HCL变异型、脾弥漫性红髓淋巴瘤)的诊断、风险分层与治疗进展。
主要发现
- HCL诊断基于毛细胞形态学证据、基于CD11c、CD103、CD123和CD25表达的HCL免疫学评分3或4分、可明确肿瘤骨髓浸润程度的环钻活检及BRAFV600E体细胞突变。
- HCL进展风险基于巨脾、白细胞增多、外周血毛细胞高数量及免疫球蛋白重链可变区基因突变状态。
- VH4-34阳性HCL病例、伴TP53突变的HCL及HCL-V与不良预后相关。
关键数值与推荐
- HCL免疫学评分基于CD11c、CD103、CD123和CD25表达,评分为3或4分。
- 诊断依据包括毛细胞形态学证据、环钻活检及BRAFV600E体细胞突变。
- 风险分层因素包括巨脾、白细胞增多、外周血毛细胞高数量及免疫球蛋白重链可变区基因突变状态。
临床怎么用
- 仅症状性HCL患者应接受治疗。
- 一线HCL患者适用风险适应嘌呤类似物化疗。
- 克拉屈滨联合利妥昔单抗的化学免疫治疗是日益增多的治疗选择。
- 复发/难治疾病管理基于BRAF抑制剂联合利妥昔单抗、MEK抑制剂、靶向CD22的重组免疫偶联物、BTK抑制剂和Bcl-2抑制剂,但最佳顺序尚待确定。
局限性
- 不同治疗的最佳顺序尚待确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogenous group of mature lymphoid B-cell disorders characterized by the identification of hairy cells, a specific genetic profile, a different clinical course and the need for appropriate treatment. DIAGNOSIS: Diagnosis of HCL is based on morphological evidence of hairy cells, an HCL immunologic score of 3 or 4 based on the CD11c, CD103, CD123, and CD25 expression, the trephine biopsy which makes it possible to specify the degree of tumoral bone marrow infiltration and the presence of BRAFV600E somatic mutation. RISK STRATIFICATION: Progression of patients with HCL is based on a large splenomegaly, leukocytosis, a high number of hairy cells in the peripheral blood, and the immunoglobulin heavy chain variable region gene mutational status. VH4-34 positive HCL cases are associated with a poor prognosis, as well as HCL with TP53 mutations and HCL-V. TREATMENT: Patients should be treated only if HCL is symptomatic. Chemotherapy with risk-adapted therapy purine analogs (PNAs) are indicated in first-line HCL patients. The use of chemo-immunotherapy combining cladribine (CDA) and rituximab (R) represents an increasingly used therapeutic approach. Management of relapsed/refractory disease is based on the use of BRAF inhibitors (BRAFi) plus R, MEK inhibitors (MEKi), recombinant immunoconjugates targeting CD22, Bruton tyrosine kinase inhibitors (BTKi), and Bcl-2 inhibitors (Bcl-2i). However, the optimal sequence of the different treatments remains to be determined.
引用
- Troussard X, Maître E, Paillassa J, et al. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies. Am J Hematol. 2024. PMID: 38440808. doi:10.1002/ajh.27240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。